James E Bates

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/986190/publications.pdf

Version: 2024-02-01

		643344	651938
57	778	15	25
papers	citations	h-index	g-index
57	57	57	1397
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Geographic access to brachytherapy services in the United States. Brachytherapy, 2022, 21, 29-32.	0.2	12
2	Comparative Effectiveness of Proton Therapy versus Photon Radiotherapy in Adolescents and Young Adults for Classical Hodgkin Lymphoma. International Journal of Particle Therapy, 2022, 8, 21-27.	0.9	0
3	Human Papillomavirus–Negative Oropharyngeal Cancer Survival Outcomes Based on Primary Treatment: National Cancer Database Analysis. Otolaryngology - Head and Neck Surgery, 2022, 167, 100-108.	1.1	1
4	Demographics of ASTRO Student Members and Potential Implications for Future U.S. Radiation Oncology Workforce Diversity. Advances in Radiation Oncology, 2022, 7, 100834.	0.6	7
5	HPV as a Carcinomic Driver in Head and Neck Cancer: a De-escalated Future?. Current Treatment Options in Oncology, 2022, 23, 325-332.	1.3	7
6	Retromolar trigone squamous cell carcinoma: A population-based analysis of survival. Oral Oncology, 2022, 127, 105767.	0.8	1
7	An integrated approach to cardioprotection in lymphomas. Lancet Haematology,the, 2022, 9, e445-e454.	2.2	5
8	Unfilled Positions in the 2022 Radiation Oncology Match: A Reduction in Positions. Practical Radiation Oncology, 2022, 12, e245-e247.	1.1	2
9	The Geography of Employment Outcomes for Radiation Oncology Graduates in 2019. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1119-1123.	0.4	5
10	Resident Considerations for Virtual Interviews in Radiation Oncology: Perspectives From the Sunshine State. Advances in Radiation Oncology, 2021, 6, 100591.	0.6	4
11	In reply to Kumar et al, Is TORS for oropharyngeal squamous cell carcinoma being done more often than actually indicated?. Head and Neck, 2021, 43, 1378-1379.	0.9	0
12	Second tumor risk in children treated with proton therapy. Pediatric Blood and Cancer, 2021, 68, e28941.	0.8	23
13	Radiation Oncology Application and Match Patterns, Pre- and Post-SOAP (Supplemental Offer and) Tj ETQq1 1 0.	.784314 r ₎ 1.1	gBT/Overlo <mark>ck</mark>
14	Vision loss following high-dose proton-based radiotherapy for skull-base chordoma and chondrosarcoma. Radiotherapy and Oncology, 2021, 158, 125-130.	0.3	12
15	Unfilled Positions in the 2021 Radiation Oncology Match. Practical Radiation Oncology, 2021, 11, 323-324.	1.1	5
16	Radiation-Associated Coronary Disease in Young Cancer Survivors. JACC: CardioOncology, 2021, 3, 393-396.	1.7	5
17	Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the Childhood Cancer Survivor Study. Radiotherapy and Oncology, 2021, 163, 199-208.	0.3	17
18	Geography of the Radiation Oncology Alternative Payment Model. JCO Oncology Practice, 2021, 17, 770-772.	1.4	1

#	Article	IF	CITATIONS
19	The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era. Practical Radiation Oncology, 2020, 10, e147-e154.	1.1	51
20	Unfilled Positions in the 2020 Radiation Oncology Residency Match: No Longer an Isolated Event. Practical Radiation Oncology, 2020, 10, e307-e308.	1.1	22
21	Visual decline in pediatric survivors of brain tumors following radiotherapy. Acta Oncol $ ilde{A}^3$ gica, 2020, 59, 1257-1262.	0.8	5
22	Radiotherapy in Early-stage Gastric MALT. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 770-775.	0.6	4
23	Development and validation of an age-scalable cardiac model with substructures for dosimetry in late-effects studies of childhood cancer survivors. Radiotherapy and Oncology, 2020, 153, 163-171.	0.3	7
24	The Florida Radiation Oncology Resident Experience During Coronavirus Disease 2019: Perspectives and Recommendations. Advances in Radiation Oncology, 2020, 5, 727-731.	0.6	3
25	Comparing national practice versus standard guidelines for the use of adjuvant treatment following robotic surgery for oropharyngeal squamous cell carcinoma. Head and Neck, 2020, 42, 2602-2606.	0.9	8
26	Response Rate and Nonresponse Bias in Oncology Survey Studies. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 229-230.	0.6	16
27	Long-Term Outcomes in 10-Year Survivors of Early-Stage Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 522-529.	0.4	2
28	Geographic Distribution of Radiation Oncologists in the United States. Practical Radiation Oncology, 2020, 10, e436-e443.	1.1	27
29	Risk of brain metastases in T1–3N0 NSCLC: a population-based analysis. Lung Cancer Management, 2020, 9, LMT25.	1.5	8
30	Risk Factors Impacting Operative Mortality and Overall Survival in Adults Treated for Skull Base Chordoma and Chondrosarcoma. , 2020, 81, .		0
31	Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer Database. Radiotherapy and Oncology, 2019, 138, 75-79.	0.3	11
32	Tomayto, tomahto: prescription dose and mean heart dose in evaluating the cardiac impact of involved-field radiation therapy for Hodgkin lymphoma survivors. Acta Oncológica, 2019, 58, 1783-1785.	0.8	2
33	Locally advanced hypopharyngeal and laryngeal cancer: Influence of HPV status. Radiotherapy and Oncology, 2019, 140, 6-9.	0.3	17
34	The High Number of Unfilled Positions in the 2019 Radiation Oncology Residency Match: Temporary Variation or Indicator of Important Change?. Practical Radiation Oncology, 2019, 9, 300-302.	1.1	28
35	Prognostic Significance of Sites of Visceral Metastatic Disease in Prostate Cancer: A Population-based Study of 12,180 Patients. Clinical Genitourinary Cancer, 2019, 17, 260-267.	0.9	17
36	Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 2019, 37, 1090-1101.	0.8	103

#	Article	IF	CITATIONS
37	Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Singleâ€institution outcomes. Head and Neck, 2019, 41, 2309-2314.	0.9	37
38	The utilization patterns and comparative effectiveness of systemic therapy with high-dose thoracic radiotherapy or low-dose thoracic radiotherapy versus systemic therapy alone in newly diagnosed metastatic non-small cell lung cancer patients. Journal of Radiation Oncology, 2019, 8, 425-438.	0.7	0
39	Curative-dose Chemoradiotherapy Versus Total Laryngectomy For Stage T3-T4 Squamous Cell Carcinoma of the Larynx. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 527-533.	0.6	17
40	Cardiac MRI for Detecting Early Cardiac Toxicity after Proton Therapy for Hodgkin Lymphoma. International Journal of Particle Therapy, 2019, 5, 41-44.	0.9	5
41	Impact of Right-sided Primary Tumor Location Among Patients With Oligometastatic Colorectal Cancer Treated With Stereotactic Body Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1172-1175.	0.6	0
42	Radiation Therapy for Aggressive Fibromatosis: The Association Between Local Control and Age. International Journal of Radiation Oncology Biology Physics, 2018, 100, 997-1003.	0.4	23
43	The Benefit of Adjuvant Radiotherapy in High-grade Nonmetastatic Retroperitoneal Soft Tissue Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 274-279.	0.6	36
44	To Treat or Not to Treat? A Postmastectomy Question. International Journal of Radiation Oncology Biology Physics, 2018, 102, 284.	0.4	4
45	Radiotherapy for Brain Metastases From Renal Cell Carcinoma in the Targeted Therapy Era. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 439-443.	0.6	21
46	Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database. Radiotherapy and Oncology, 2017, 124, 325-330.	0.3	4
47	Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 1903-1910.	0.6	25
48	Survival after subsequent non-Hodgkin's lymphoma and non-small cell lung cancer in patients with malignant thymoma. Journal of Thoracic Disease, 2016, 8, 3605-3613.	0.6	2
49	Repeat courses of SRS in patients initially treated with SRS alone for brain-metastatic melanoma. Melanoma Management, 2016, 3, 97-104.	0.1	5
50	Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. International Journal of Radiation Oncology Biology Physics, 2016, 96, 372-378.	0.4	15
51	Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. Journal of Neuro-Oncology, 2016, 129, 251-258.	1.4	49
52	Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. Journal of Neuro-Oncology, 2015, 125, 411-418.	1.4	14
53	Neonatal dentate nucleus T2 hyperintensity after in utero metronidazole exposure. Neurology, 2015, 85, 1006-1006.	1.5	3
54	Pearls & Dy-sters: Cough headache secondary to Chiari malformation type I. Neurology, 2014, 83, e149-51.	1.5	3

#	Article	IF	CITATIONS
55	Spinal Drop Metastasis in Myxopapillary Ependymoma: A Case Report and a Review of Treatment Options. Rare Tumors, 2014, 6, 79-82.	0.3	10
56	Malignant peripheral nerve sheath tumors (MPNST): A SEER analysis of incidence across the age spectrum and therapeutic interventions in the pediatric population. Pediatric Blood and Cancer, 2014, 61, 1955-1960.	0.8	54
57	Impact of Type of Treatment Center and Access to Care on Mortality and Survival for Skull Base Chordoma and Chondrosarcoma. Journal of Neurological Surgery, Part B: Skull Base, 0, , .	0.4	3